Lung function testing in patients with pulmonary arterial hypertension;Exploración funcional pulmonar en pacientes con hipertensión arterial pulmonar

Archivos de Bronconeumologia

Volumn 41, Issue 7, 2005, Pages 380-384

  Martin Escribano P ^a   Gomez Sanchez M A ^a   Diaz De Atauri M J ^a   Palomera Frade, J ^a   Martin Garcia I ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Diagnosis; Lung function tests; Pulmonary hypertension: physiopathology

Indexed keywords

CARBON DIOXIDE;

ADULT; ARTICLE; COLLAGEN DISEASE; CONTROLLED STUDY; FORCED EXPIRATORY VOLUME; HEART SEPTUM DEFECT; HUMAN; HYPOXEMIA; IDIOPATHIC DISEASE; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SPAIN; TOTAL LUNG CAPACITY; TOXIC OIL SYNDROME;

EID: 23044484992     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076968     Document Type: Article

References (35)

1. World Symposium on Pulmonary Hypertension 1998 Evian. Geneve: World Health Organisation.
2. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:S5-S12.
3. Toxic Epidemic Syndrome Study Group. Toxic epidemic syndrome. Spain 1981. Lancet. 1982;ii:697-702.
4. Report Working Party "Standardization of Lung Function Tests". Official Statement of the European Respiratory Society. Eur Respir J. 1993;6 Suppl 16:5-52.
5. Martín Escribano P. Respiratory functional studies during the neuromyopathic phase and last functional studies. Eur J Respir Dis. 1983;64:423.
6. Martín Escribano P, Fernández Sánchez-Alarcos JM, Domínguez Lozano MJ, Díaz de Atauri MJ, Barbosa Ayúcar C, Cantalapiedra JA, et al. Exploration fonctionelle aux differentes stades du syndrome du a l'huile toxique. Bull Eur Physiopathol Respir. 1984;20:307-12.
7. Díaz de Atauri MJ, Ramis Pedromingo MM, Martín Escribano P. Disnea en pacientes afectos por ingesta de aceite tóxico; ¿origen psicosomático o secundario a alteración funcional pulmonar? Med Clin (Barc). 1986;87:523.
8. Gómez Sánchez MA, Mestre de Juan MJ, Gómez Pajuelo C, Díaz de Atauri MJ, Martínez Tello FJ. Pulmonary hypertension due to toxic oil syndrome: a clinico-pathological study. Chest. 1989;95:325-31.
9. Gómez Sánchez MA, Díaz de Atauri MJ, Alonso Gutiérrez M, Martín Escribano P, Sáenz de la Calzada C, Gómez Pajuelo, et al. Dynamic pulmonary arterial hypertension: a new form of pulmonary hypertension in patients with impaired pulmonary diffusing capacity due to toxic oil syndrome. Cor Vasa. 1990;32:211-7.
10. Martín Escribano P, Díaz de Atauri MJ. Síndrome tóxico y asma. Arch Bronconeumol. 1990;26:377-8.
11. Martín Escribano P, Díaz de Atauri MJ, Gómez Sánchez MA. Persistence of respiratory abnormalities four years after the onset of toxic oil syndrome. Chest. 1991;100:336-9.
12. Gómez Sánchez MA, Sáenz de la Calzada C, Gómez Pajuelo C, Martínez Tello FJ, Mestre de Juan MJ, James TN. Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome. J Am Coll Cardiol. 1991;18:1539-45.
13. Díaz de Atauri MJ. Afectación pulmonar en el síndrome del aceite tóxico: estudio evolutivo de nueve años de enfermedad [tesis doctoral]. Madrid: Universidad Autónoma de Madrid; 1992.
14. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension. Ann Inter Med. 1987;107:216-23.
15. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111-7.
16. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345:1465-72.
17. Loscalzo J. Genetic clues to the cause of primary pulmonary hypertension. N Engl J Med. 2001;345:367-71.
18. Olschewski H, Rose F, Grunig E, Ghofrani HA, Walmarth D, Schultz R, et al. Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med. 2001;138:367-77.
19. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheelar L, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 2001;68:92-102.
20. Theegarten D, Anhenn O, Aretz S, Maass M, Mogilevski G. Detection of Chlamydia pneumoniae in unexplained pulmonary hypertension. Eur Respir J. 2002;19:192-4.
21. Lee AD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998;101:927-34.
22. Gibbs JSR, British Cardiac Society. Recommendations on the management of pulmonary hypertension in clinical practice. Thorax. 2001;86 Suppl 1:1-13.
23. Conte JV, Borja MJ, Patel CB, Yang SC, Jhaveri RM, Orens JB. Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg. 2001;72:1673-9.
24. Kessler R, Chaouat A, Weitzenblum E, Oswald M, Ehrhart M, Apprill M, et al. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J. 1996;9:787-94.
25. Naeije R, Barberá JA. Pulmonary hypertension associated with COPD. Crit Care. 2001;5:286-9.
26. Burke CM, Glandville AR, Morris AJ, Rubin D, Harvey JA, Theodore J, et al. Pulmonary function in advanced pulmonary hypertension. Thorax. 1987;42:131-5.
27. Romano AM, Tomaselli S, Gualtieri G, Zoia MC, Fanfulla F, Berrayah L, et al. Respiratory function in precapillary pulmonary hypertension. Monaldi Arch Chest Dis. 1993;48:201-4.
28. Waxman AB. Pulmonary function test abnormalities in pulmonary vascular disease and chronic heart failure. Clin Chest Med. 2001;22:751-8.
29. Steenhuis LH, Groen HJM, Koeter GH, Van den Mark TW. Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension. Eur Respir J. 2000;16:276-81.
30. Bernstein RJ, Ford RL, Clausen JL, Moser KM. Membrane diffusion and capillary blood volumen in chronic thromboembolic pulmonary hypertension. Chest. 1996;110:1430-6.
31. Rubin LJ. Primary pulmonary hypertension. ACCP Consensus Statement. Chest. 1993;104:236-50.
32. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001;104:429-35.
33. Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr, Bein M, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med. 1983;75:65-74.
34. Paciocco G, Martínez FJ, Bossone E, Pielsticker E, Guillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001;17:647-52.
35. McMahon CJ, Kadkin J, Nihill MR. Rapid regression of primary pulmonary hypertension. Heart. 2001;86:E1.